Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BrightLight
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
01
Overview
BrightLight is an investigational pharmaceutical drug developed by Intra-Cellular Therapies, currently in late-stage development with Phase 3 trials underway. It is being investigated for the treatment of central nervous system (CNS) disorders, specifically schizophrenia. Johnson & Johnson is in the process of acquiring Intra-Cellular Therapies, which includes BrightLight in its pipeline, indicating a strategic expansion into CNS and mental health.
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR7 (5-hydroxytryptamine receptor 7)DRD2 (Dopamine D2 Receptor)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on BrightLight.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BrightLight.